IP Library › Granted Patent US 12,365,737
Granted Patent B2
US 12,365,737 · App. 18/817,109 · Granted Jul 22, 2025

Anti-IL-18BP antibodies

Inventors: Robert A. Horlick (San Diego, CA); Helen Toni Jun (San Diego, CA); Magdalena S. Willen (San Diego, CA); Christine M. Chidester (San Diego, CA); Mark G. Barrett (Wellesley, MA); David J. King (Encinitas, CA); Deborah A. Witherden (San Diego, CA)
Assignee: Lassen Therapeutics, Inc.
C07K16/2866A61K39/3955A61K38/20C07K14/715C07K2317/24C07K2317/33C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,737
App. No.
18/817,109
Granted
Jul 22, 2025
Kind
B2
Abstract

Provided are antibodies that bind to interleukin-18 binding protein (IL-18BP) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers and other diseases.

Claims (114)

1. An antibody specific for interleukin-18 binding protein (IL-18BP), wherein the antibody interferes with the binding of IL-18 to IL-18BP, and wherein the antibody comprises a heavy chain variable region (V H ) that comprises complementarity determining region V H CDR1, V H CDR2, and V H CDR3 sequences and a light chain variable region (V L ) that comprises complementarity determining region V L CDR1, V L CDR2, and V L CDR3 sequences, wherein:

a. the V H CDR1 sequence comprises the amino acid sequence of TQDYNAH (SEQ ID NO: 169);

b. the V H CDR2 sequence comprises the amino acid sequence of YIHYSGQTYYNPSLKS (SEQ ID NO: 170);

c. the V H CDR3 sequence comprises the amino acid sequence of NFGSIYVNYFDY (SEQ ID NO: 171);

d. the V L CDR1 sequence comprises the amino acid sequence of SASSSVSYMY (SEQ ID NO: 172);

e. the V L CDR2 sequence comprises the amino acid sequence of TSNLAS (SEQ ID NO: 173); and

f. the V L CDR3 sequence comprises an amino acid sequence of QQYHSYPT (SEQ ID NO: 174) or an amino acid sequence comprising 1 to 2 amino acid substitutions thereof.

2. The antibody of claim 1 , wherein the V L CDR3 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 174, 228, 234, 240, and 252.

3. The antibody of claim 1 , wherein:

a. the V H comprises a sequence at least 70% identical to SEQ ID NO: 321, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 322;

b. the V H comprises a sequence at least 70% identical to SEQ ID NO: 339, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 340;

c. the V H comprises a sequence at least 70% identical to SEQ ID NO: 341, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 342;

d. the V H comprises a sequence at least 70% identical to SEQ ID NO: 343, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 344; or

e. the V H comprises a sequence at least 70% identical to SEQ ID NO: 347, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 3481.

4. The antibody of claim 1 , wherein the antibody comprises an IgA IgD, IgE, IgG, or IgM Fc domain, or a hybrid and/or variant thereof.

5. The antibody of claim 4 , wherein the IgA Fc domain is IgA1 or IgA2.

6. The antibody of claim 4 , wherein the IgG Fc domain is IgG1, IgG2, IgG3, or IgG4.

7. The antibody of claim 4 , wherein the Fc domain is a human Fc domain.

8. The antibody of claim 1 , wherein the antibody comprises variant IgG Fc domain with increased effector function in humans relative to a wild type IgG Fc domain.

9. The antibody of claim 8 , wherein the variant IgG Fc domain is an IgG1 or IgG3 Fc domain.

10. The antibody of claim 1 , wherein the antibody comprises variant IgG Fc domain with decreased effector function in humans relative to a wild type IgG Fc domain.

11. The antibody of claim 10 , wherein the variant IgG Fc domain is an IgG2 or IgG4 Fc domain.

12. The antibody of claim 1 , wherein the antibody is a monoclonal antibody, humanized antibody or an scFv.

13. A pharmaceutical composition comprising the antibody of claim 1 , and optionally a pharmaceutically acceptable carrier.

14. An antibody specific for interleukin-18 binding protein (IL-18BP), wherein the antibody interferes with the binding of IL-18 to IL-18BP, and wherein the antibody comprises a heavy chain variable region (V H ) that comprises complementarity determining region V H CDR1, V H CDR2, and V H CDR3 sequences and a light chain variable region (V L ) that comprises complementarity determining region V L CDR1, V L CDR2, and V L CDR3 sequences, wherein:

a. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 1-3, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 4-6, respectively;

b. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 7-9, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 10-12, respectively;

c. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 13-15, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 16-18, respectively;

d. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 19-21, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 22-24, respectively;

e. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 25-27, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 28-30, respectively;

f. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 31-33, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 34-36, respectively;

g. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 37-39, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 40-42, respectively;

h. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 43-45, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 46-48, respectively;

i. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 49-51, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 52-54, respectively;

j. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 55-57, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 58-60, respectively;

k. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 61-63, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 64-66, respectively;

l. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 67-69, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 70-72, respectively;

m. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 73-75, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 76-78, respectively;

n. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 79-81, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 82-84, respectively;

o. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 85-87, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 88-90, respectively;

p. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 91-93, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 94-96, respectively;

q. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 97-99, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 100-102, respectively;

r. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 103-105, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 106-108, respectively;

s. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 109-111, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 112-114, respectively;

t. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 115-117, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 118-120, respectively;

u. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 121-123, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 124-126, respectively;

v. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 127-129, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 130-132, respectively;

w. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 133-135, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 136-138, respectively;

x. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 139-141, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 142-144, respectively;

y. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 145-147, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 148-150, respectively;

z. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 151-153, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 154-156, respectively;

aa. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 157-159, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 160-162, respectively;

bb. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 163-165, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 166-168, respectively;

cc. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 175-177, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 178-180, respectively;

dd. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 181-183, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 184-186, respectively;

ee. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 187-189, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 190-192, respectively;

ff. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 193-195, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 196-198, respectively;

gg. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 199-201, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 202-204, respectively;

hh. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 205-207, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 208-210, respectively;

ii. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 211-213, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 238-240, respectively;

jj. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 217-219, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 220-222, respectively;

kk. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 241-243, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 232-234, respectively;

ll. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 241-243, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 238-240, respectively; or

mm. the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 241-243, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 244-246, respectively.

15. The antibody of claim 1 , wherein:

a. the V H comprises a sequence at least 70% identical to SEQ ID NO: 265, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 266;

b. the V H comprises a sequence at least 70% identical to SEQ ID NO: 267, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 268;

c. the V H comprises a sequence at least 70% identical to SEQ ID NO: 269, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 270;

d. the V H comprises a sequence at least 70% identical to SEQ ID NO: 271, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 272;

e. the V H comprises a sequence at least 70% identical to SEQ ID NO: 273, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 274;

f. the V H comprises a sequence at least 70% identical to SEQ ID NO: 275, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 276;

g. the V H comprises a sequence at least 70% identical to SEQ ID NO: 277, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 278;

h. the V H comprises a sequence at least 70% identical to SEQ ID NO: 279, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 280;

i. the V H comprises a sequence at least 70% identical to SEQ ID NO: 281, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 282;

j. the V H comprises a sequence at least 70% identical to SEQ ID NO: 283, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 284;

k. the V H comprises a sequence at least 70% identical to SEQ ID NO: 285, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 286;

l. the V H comprises a sequence at least 70% identical to SEQ ID NO: 287, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 288;

m. the V H comprises a sequence at least 70% identical to SEQ ID NO: 289, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 290;

n. the V H comprises a sequence at least 70% identical to SEQ ID NO: 291, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 292;

o. the V H comprises a sequence at least 70% identical to SEQ ID NO: 293, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 294;

p. the V H comprises a sequence at least 70% identical to SEQ ID NO: 295, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 296;

q. the V H comprises a sequence at least 70% identical to SEQ ID NO: 297, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 298;

r. the V H comprises a sequence at least 70% identical to SEQ ID NO: 299, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 300;

s. the V H comprises a sequence at least 70% identical to SEQ ID NO: 301, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 302;

t. the V H comprises a sequence at least 70% identical to SEQ ID NO: 303, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 304;

u. the V H comprises a sequence at least 70% identical to SEQ ID NO: 305, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 306;

v. the V H comprises a sequence at least 70% identical to SEQ ID NO: 307, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 308;

w. the V H comprises a sequence at least 70% identical to SEQ ID NO: 309, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 310;

x. the V H comprises a sequence at least 70% identical to SEQ ID NO: 311, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 312;

y. the V H comprises a sequence at least 70% identical to SEQ ID NO: 313, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 314;

z. the V H comprises a sequence at least 70% identical to SEQ ID NO: 315, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 316;

aa. the V H comprises a sequence at least 70% identical to SEQ ID NO: 317, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 318;

bb. the V H comprises a sequence at least 70% identical to SEQ ID NO: 319, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 320;

cc. the V H comprises a sequence at least 70% identical to SEQ ID NO: 323, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 324;

dd. the V H comprises a sequence at least 70% identical to SEQ ID NO: 325, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 326;

ee. the V H comprises a sequence at least 70% identical to SEQ ID NO: 327, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 328;

ff. the V H comprises a sequence at least 70% identical to SEQ ID NO: 329, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 330;

gg. the V H comprises a sequence at least 70% identical to SEQ ID NO: 331, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 332;

hh. the V H comprises a sequence at least 70% identical to SEQ ID NO: 333, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 334;

ii. the V H comprises a sequence at least 70% identical to SEQ ID NO: 335, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 336;

jj. the V H comprises a sequence at least 70% identical to SEQ ID NO: 337, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 338;

kk. the V H comprises a sequence at least 70% identical to SEQ ID NO: 345, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 342;

ll. the V H comprises a sequence at least 70% identical to SEQ ID NO: 345, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 344; or

mm. the V H comprises a sequence at least 70% identical to SEQ ID NO: 345, and the V L comprises a sequence at least 70% identical to SEQ ID NO: 346.

16. The antibody of claim 14 , wherein the antibody comprises an IgA IgD, IgE, IgG or IgM Fc domain, mor a hybrid and/or variant thereof.

17. The antibody of claim 16 , wherein the IgA Fc domain is IgA1 or IgA2.

18. The antibody of claim 16 , wherein the IgG Fc domain is IgG1, IgG2, IgG3, or IgG4.

19. The antibody of claim 16 , wherein the Fc domain is a human Fc domain.

20. The antibody of claim 14 , wherein the antibody comprises variant IgG Fc domain with increased effector function in humans relative to a wild type IgG Fc domain.

21. The antibody of claim 20 , wherein the variant IgG Fc domain is an IgG1 or IgG3 Fc domain.

22. The antibody of claim 14 , wherein the antibody comprises variant IgG Fc domain with decreased effector function in humans relative to a wild type IgG Fc domain.

23. The antibody of claim 22 , wherein the variant IgG Fc domain is an IgG2 or IgG4 Fc domain.

24. The antibody of claim 14 , wherein the antibody is a monoclonal antibody, humanized antibody or an scFv.

25. A pharmaceutical composition comprising the antibody of claim 14 , and optionally a pharmaceutically acceptable carrier.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: LASSEN THERAPEUTICS, INC.
To: EDGEWOOD ONCOLOGY, INC.
Reel/Frame 073147/0941 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2025
From: JUNIPER DISCOVERY, INC.
To: SHASTA THERAPEUTICS, INC.
Reel/Frame 072395/0223 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2025
From: HORLICK, ROBERT A.; JUN, HELEN TONI; WILLEN, MAGDALENA S.; CHIDESTER, CHRISTINE M.; BARRETT, MARK G.; KING, DAVID J.
To: JUNIPER DISCOVERY, INC.
Reel/Frame 072959/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2025
From: HORLICK, ROBERT A.; JUN, HELEN TONI; WILLEN, MAGDALENA S.; CHIDESTER, CHRISTINE M.; BARRETT, MARK G.; KING, DAVID J.
To: JUNIPER DISCOVERY, INC.
Reel/Frame 072680/0217 →
CHANGE OF NAME Recorded Jun 2, 2025
From: LASSEN THERAPEUTICS 1, INC.
To: LASSEN THERAPEUTICS, INC.
Reel/Frame 071468/0121 →
MERGER Recorded Dec 31, 2024
From: SHASTA THERAPEUTICS, INC.
To: LASSEN THERAPEUTICS 1, INC.
Reel/Frame 069711/0373 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2024
From: JUNIPER DISCOVERY, INC.
To: SHASTA THERAPEUTICS, INC.
Reel/Frame 069711/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2024
From: WITHERDEN, DEBORAH ALICE
To: JUNIPER DISCOVERY, INC.
Reel/Frame 069711/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2024
From: HORLICK, ROBERT A.; JUN, HELEN TONI; WILLEN, MAGDALENA S.; CHIDESTER, CHRISTINE M.; BARRETT, MARK G.; KING, DAVID J.
To: JUNIPER DISCOVERY, INC.
Reel/Frame 069711/0303 →
Continuity (5)
Continuation PCTUS2024010447 · Jan 5, 2024
Provisional Application 63596580 · Nov 6, 2023
Provisional Application 63590348 · Oct 13, 2023
Provisional Application 63437526 · Jan 6, 2023
Related Publication 20240417479A1 · Dec 19, 2024
References Cited (250)
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5464758A · Gossen et al. · 1995 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5814618A · Bujard et al. · 1998 [cited by applicant]
US 6210922B1 · Côté et al. · 2001 [cited by applicant]
US 6376190B1 · Gold et al. · 2002 [cited by applicant]
US 6387620B1 · Smith et al. · 2002 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6765087B1 · Casterman et al. · 2004 [cited by applicant]
US 6838254B1 · Hamers et al. · 2005 [cited by applicant]
US 7029872B2 · Gerngross · 2006 [cited by applicant]
US 7030226B2 · Sun et al. · 2006 [cited by applicant]
US 7112715B2 · Chambon et al. · 2006 [cited by applicant]
US 7166697B1 · Galanis et al. · 2007 [cited by applicant]
US 7217797B2 · Hinton et al. · 2007 [cited by applicant]
US 7244592B2 · Hoogenboom et al. · 2007 [cited by applicant]
US 7326681B2 · Gerngross · 2008 [cited by applicant]
US 7425619B2 · Koenig et al. · 2008 [cited by applicant]
US 7462697B2 · Couto et al. · 2008 [cited by applicant]
US 7629163B2 · Gerngross · 2009 [cited by applicant]
US 7662925B2 · Lazar et al. · 2010 [cited by applicant]
US 7700321B2 · McPherson et al. · 2010 [cited by applicant]
US 7732570B2 · Hinton et al. · 2010 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8436148B2 · Dinarello et al. · 2013 [cited by applicant]
US 8993731B2 · Tyson · 2015 [cited by applicant]
US 9073994B2 · Honjo et al. · 2015 [cited by applicant]
US 9084776B2 · Korman et al. · 2015 [cited by applicant]
US 9102725B2 · Korman et al. · 2015 [cited by applicant]
US 9102727B2 · Freeman et al. · 2015 [cited by applicant]
US 9102728B2 · Tyson · 2015 [cited by applicant]
US 9181342B2 · Davis · 2015 [cited by applicant]
US 9217034B2 · Li et al. · 2015 [cited by applicant]
US 9387247B2 · Korman et al. · 2016 [cited by applicant]
US 9393301B2 · Honjo et al. · 2016 [cited by applicant]
US 9402899B2 · Honjo et al. · 2016 [cited by applicant]
US 9439962B2 · Honjo et al. · 2016 [cited by applicant]
US 9492539B2 · Korman et al. · 2016 [cited by applicant]
US 9492540B2 · Korman et al. · 2016 [cited by applicant]
US 20030108532A1 · Benson et al. · 2003 [cited by applicant]
US 20030118592A1 · Ledbetter et al. · 2003 [cited by applicant]
US 20030190311A1 · Dall'Acqua et al. · 2003 [cited by applicant]
US 20040175756A1 · Kolkman et al. · 2004 [cited by applicant]
US 20050037421A1 · Honda et al. · 2005 [cited by applicant]
US 20050048512A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050053973A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050089932A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050221384A1 · Kolkman et al. · 2005 [cited by applicant]
US 20060058510A1 · Skerra et al. · 2006 [cited by applicant]
US 20060173170A1 · Chamberlain et al. · 2006 [cited by applicant]
US 20070082365A1 · Lipovsek et al. · 2007 [cited by applicant]
US 20070092521A1 · McPherson et al. · 2007 [cited by applicant]
US 20070111281A1 · Sondermann et al. · 2007 [cited by applicant]
US 20070148170A1 · Desjarlais et al. · 2007 [cited by applicant]
US 20080139791A1 · Lipovsek et al. · 2008 [cited by applicant]
US 20080206246A1 · Ravetch et al. · 2008 [cited by applicant]
US 20080220049A1 · Chen et al. · 2008 [cited by applicant]
US 20090010921A1 · Umana et al. · 2009 [cited by applicant]
US 20090017023A1 · Koenig et al. · 2009 [cited by applicant]
US 20090082274A1 · Stumpp et al. · 2009 [cited by applicant]
US 20090163699A1 · Chamberlain et al. · 2009 [cited by applicant]
US 20090226421A1 · Parren et al. · 2009 [cited by applicant]
US 20100080794A1 · Tsuji et al. · 2010 [cited by applicant]
US 20100092997A1 · Nakamura et al. · 2010 [cited by applicant]
US 20100143254A1 · Dall'Acqua et al. · 2010 [cited by applicant]
US 20100203046A1 · Van Vlijmen et al. · 2010 [cited by applicant]
US 20100209424A1 · Roopenian et al. · 2010 [cited by applicant]
US 20100249382A1 · Desjarlais et al. · 2010 [cited by applicant]
US 20100255013A1 · Presta · 2010 [cited by applicant]
US 20120039906A1 · Olive · 2012 [cited by applicant]
US 20130245104A1 · De Fougerolles et al. · 2013 [cited by applicant]
US 20140112915A1 · Bardroff et al. · 2014 [cited by applicant]
US 20140147454A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140243399A1 · Schrum et al. · 2014 [cited by applicant]
US 20140364341A1 · Mansfield et al. · 2014 [cited by applicant]
US 20150111248A1 · Bancel et al. · 2015 [cited by applicant]
US 20150203579A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20190070262A1 · Ring et al. · 2019 [cited by applicant]
US 20230027029A1 · Zhang et al. · 2023 [cited by applicant]
WO WO9311161A1 · 1993 [cited by applicant]
WO WO9413804A1 · 1994 [cited by applicant]
WO WO9909063A1 · 1999 [cited by applicant]
WO WO0042072A2 · 2000 [cited by applicant]
WO WO0107480A2 · 2001 [cited by applicant]
WO WO0220565A2 · 2002 [cited by applicant]
WO WO2004016750A2 · 2004 [cited by applicant]
WO WO2005047337A1 · 2005 [cited by applicant]
WO WO2006079372A1 · 2006 [cited by applicant]
WO WO2012177595A1 · 2012 [cited by applicant]
WO WO2012177595A9 · 2013 [cited by applicant]
WO WO2014126277A1 · 2014 [cited by applicant]
WO WO2015032932A1 · 2015 [cited by applicant]
WO WO2016139297A1 · 2016 [cited by applicant]
WO WO2018060447A1 · 2018 [cited by applicant]
WO WO2019051015A1 · 2019 [cited by applicant]
WO WO2019213686A1 · 2019 [cited by applicant]
WO WO2021146590A2 · 2021 [cited by applicant]
WO WO2023143535A1 · 2023 [cited by applicant]
WO WO2023178192A1 · 2023 [cited by applicant]
WO WO2023215834A1 · 2023 [cited by applicant]
WO WO2024148232A2 · 2024 [cited by applicant]
WO WO2024148241A1 · 2024 [cited by applicant]
WO WO2024148243A1 · 2024 [cited by applicant]
WO WO2025003753A1 · 2025 [cited by applicant]
Aalberse, R.C. et al. (2002). “IgG4 breaking the rules,” Immunology 105:9-19. [cited by applicant]
Allen, D., et al.; “Validation of peptide mapping for protein identity and genetic stability. Biologics and biotechnology section, pharmaceutical research and manufacturers of America,” Biologicals.; 24(3):255-574 (1996… [cited by applicant]
Altschul, S. F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Research (1997); 25(17): 3389-3402. [cited by applicant]
Anicetti, et al., Purity analysis of protein pharmaceuticals produced by recombinant DNA technology, Trends in Biotechnology, Dec. 1989, 7(12); pp. 342-349. [cited by applicant]
Bird et al., Single-chain antigen-binding proteins. Science; 242(4877):423-426 (1988). [cited by applicant]
Bitter et al. Expression and secretion vectors for yeast. Methods Enzymol 153:516-544 (1987). [cited by applicant]
Bottino, C., et al.; “Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule,” J. Exp. Med.; 198(4):557-567 (2003). [cited by applicant]
Bowers et al., Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation. J Biol Chem., 288(11):7688-7696 (2013). [cited by applicant]
Brinkman et al., The making of bispecific antibodies, Mabs; 9(2):182-212 (2017). [cited by applicant]
Broglie, et al., Light-regulated expression of a pea ribulose-1,5-bisphosphate carboxylase small subunit gene in transformed plant cells, Science, May 1984, 224(4651); pp. 838-843. [cited by applicant]
Bruner et al.: Size exclusion HPLC method for the determination of acidic fibroblast growth factor in viscous formulations. Journal of Pharmaceutical and Biomedical Analysis; 15(12):1929-1935 (1997). [cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proceedings of the National Academy of Sciences, May 1992, 89(10), pp. 4285-4289. [cited by applicant]
Chao et al., “Isolating and engineering human antibodies using yeast surface display,” Nature Protocols, Aug. 2006, 1(2), pp. 755-768. [cited by applicant]
Clynes R., et al., “Fc Receptors are Required in Passive and Active Immunity to Melanoma,” Proceedings of the National Academy of Sciences of the United States of America, Jan. 20, 1998, vol. 95, No. 2, pp. 652-656. [cited by applicant]
Co, M. S., et al., “Humanized antibodies for antiviral therapy,” Proceedings of the National Academy of Sciences (1991) 88(7):2869-2873. [cited by applicant]
Co, M.S., et al.; “Chimeric and humanized antibodies with specificity for the CD33 antigen,” J Immunol.; 148(4):1149-1154 (1992). [cited by applicant]
Colbere-Garapin, F., et al.; “A new dominant hybrid selective marker for higher eukaryotic cells,” Journal of Molecular biology, Jul. 1981, 150(1):1-14. [cited by applicant]
Coruzzi, G., et al.; “Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of ribulose-1,5-bisphosphate carboxylase,” EMBO J. (1984); 3(8):1671-1679. [cited by applicant]
Croft, M., et al.; “The significance of OX40 and OX40L to T-cell biology and immune disease,” Immunological Reviews; 229(1):173-191 (2009). [cited by applicant]
Davies, D.R., et al.; “Antibody-antigen complexes,” Annu Rev Biochem.; 59:439-473 (1990). [cited by applicant]
Davies J., et al., “Expression of GnTlll in a Recombinant Anti-CD20 CHO Production Cell Line: Expression of Antibodies with Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity for FCgammaRIII,” Biote… [cited by applicant]
Denardo et al., Comparison of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 … [cited by applicant]
Derre, L., et al. (2010). “BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.” The Journal of clinical investigation. 120(1):157-167. [cited by applicant]
Detry, S., et al.; “Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity,” J Biol Chem.; 298(5):101908, 16 pages (2022). [cited by applicant]
Ehrlich, P. et al., “Isolation of an active heavy-chain variable domain from a homogeneous rabbit antibody by cathepsin B digestion of the aminoethylated heavy chain,” Biochemistry, Aug. 1, 1980, vol. 19, No. 17, pp. 40… [cited by applicant]
Ellington et al., “In vitro selection of RNA molecules that bind specific ligands,” Nature; 346(6287):818-822 (1990). [cited by applicant]
Engelhard, et al., The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus, Proceedings of the National Academy of Sciences, Apr. 1994, 91(8); pp. 3224-3227. [cited by applicant]
Fuhrmann-Benzakein, et al., “Inducible and irreversible control of gene expression using a single transgene,” 28(23):E99, 5 pages (2000). [cited by applicant]
Gerngross, Advances in the production of human therapeutic proteins in yeasts and filamentous fungi, Nat Biotechnol., Nov. 2004, 22(11); pp. 1409-1414. [cited by applicant]
Gorman et al. “Reshaping a therapeutic CD4 antibody.” Proceedings of the National Academy of Sciences (1991); 88.10: 4181-4185. [cited by applicant]
Graham, T.L. et al. (1977). “Characteristics of a Human Cell Line Transformed by DNA From Human Adenovirus Type 5,” J. Gen. Virol., vol. 36, pp. 59-72. [cited by applicant]
Hamilton, et al., Humanization of yeast to produce complex terminally sialylated glycoproteins, Science, Sep. 2006, 313(5792); pp. 1441-1443. [cited by applicant]
Hamilton et al., Production of complex human glycoproteins in yeast. Science; 301(5637):1244-1246 (2003). [cited by applicant]
Hartman, et al., Two Dominant-Acting Selectable Markers for Gene Transfer Studies in Mammalian Cells, Proceedings of the National Academy of Sciences of the United States of America, Nov. 1988, 85(21); pp. 8047-8051. [cited by applicant]
He, L-Z., et al.; “Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice,” J Immunol.; 191(8):4174-4183 (2013). [cited by applicant]
Hochman, J. et al., “Folding and interaction of subunits at the antibody combining site,” Biochemistry, Jun. 1, 1976, vol. 15, No. 12, pp. 2706-2710. [cited by applicant]
Holliger, P., et al., ““Diabodies”: small bivalent and bispecific antibody fragments”, Proceedings of the National Academy of Sciences (1993); 90(14): 6444-6448. [cited by applicant]
Holliger, P., et al., “Engineering bispecific antibodies”, Current Opinion in Biotechnology (1993); 4(4):446-449. [cited by applicant]
Hu, S., et al., “Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts”, Cancer Research (1996); 56(13):3055-3061. [cited by applicant]
Huang et al., “Role of LAG-3 in regulatory T cells” Immunity, (2004); 21(4):503-513. [cited by applicant]
Huston, J. S., et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Ill, C. et al., “Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions,” Protein Engineering, Design and Selection, Aug. 1997, vol. 10, Issue 8, pp. 949… [cited by applicant]
Im S-H., et al.; “Rat interleukin-18 binding protein: cloning, expression, and characterization,” J Interferon Cytokine Res. (2002); 22(3):321-328. [cited by applicant]
Inbar et al., “Localization of antibody-combining sites within the variable portions of heavy and light chains”. Proceedings of the National Academy of Sciences. Sep. 1972; 69(9):2659-62. [cited by applicant]
Indra, A.K., et al.; “Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases,” Nuclei… [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/010445 dated May 7, 2024, 17 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/010447 dated Apr. 23, 2024, 17 pages. [cited by applicant]
Johnson, P., et al.; “Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study,” Clin Cancer Res.; 21(6):1321-1328 (2015). [cited by applicant]
Johnston, R.J., et al.; “The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function,” Cancer Cell, 26(6):923-937 (2014). [cited by applicant]
Jun, H.T., et al.; “Abstract 1824: Discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity,” Cancer Res. (2023) 83(7_Supplement): pp. 1824-1824. [cited by applicant]
Kelly et al., “How to study proteins by circular dichroism,” Biochim Biophys Acta; 1751(2):119-139 (2005). [cited by applicant]
Kettleborough et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.” Protein Engineering (1991); 4.7:773-783. [cited by applicant]
Kim, S.H., et al.; “Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18,” PNAS USA; 97(3):1190-1195 (2000). [cited by applicant]
Kimura, T., et al.; “Expression, purification and structural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy,” Allergol Int.; 57(4):367-376 (2008). [cited by applicant]
Kinoshita, M., et al.; “Paradoxical effect of IL-18 therapy on the severe and mild [cited by applicant]
Kohler et al., Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol.; 6(7):511-519 (1976). [cited by applicant]
Kormann, et al., Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol.; 29(2):154-157 (2011). [cited by applicant]
Kramer et al., “Transgene control engineering in mammalian cells,” Methods Mol. Biol., 308:123-143 (2005). [cited by applicant]
Kurtulus, S., et al.; “TIGIT predominantly regulates the immune response via regulatory T cells,” J Clin Invest.; Nov. 2015, 125(11):4053-4062, [with retraction], 13 pages. [cited by applicant]
Kwon, K., et al.; “High quality protein microarray using in situ protein purification,” BMC Biotechnol., Aug. 2009, 9:72; 10 pages. [cited by applicant]
Li, et al., Optimization of humanized IgGs in glycoengineered Pichia pastoris, Nature Biotechnology, Feb. 2006, 24(2); pp. 210-215. [cited by applicant]
Li, X., et al.; “Emerging immune checkpoints for cancer therapy,” Acta Oncol., Nov. 2015; 54(10):1706-1713. [cited by applicant]
Lin, et al., Automated 96-well purification of hexahistidine-tagged recombinant proteins on MagneHis Ni(2)+-particles, Methods Mol Biol., 2009, 498; pp. 129-141. [cited by applicant]
Lines, J.L., et al.; “VISTA is an immune checkpoint molecule for human T cells,” Cancer Res.; 74(7):1924-1932 (Apr. 2014). [cited by applicant]
Lobuglio et al., “Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.” Proceedings of the National Academy of Sciences (1989); 86.11:4220-4224. [cited by applicant]
Logan, et al., Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection, Proc. Natl. Acad. Sci. U.S.A., 1984, 81(12); pp. 3655-3659. [cited by applicant]
Lonberg and Huszar, “Human Antibodies from Transgenic Mice,” International Reviews of Immunology, Jan. 1995, 13(1), pp. 65-93. [cited by applicant]
Lonberg, N., “Transgenic approaches to human monoclonal antibodies,” The Pharmacology of Monoclonal Antibodies, Handbook of Experimental Pharmacology, 1994, vol. 113, pp. 49-101. [cited by applicant]
Lowy I., et al., “Isolation of Transforming DNA: Cloning the Hamster Aprt Gene,” Cell, Dec. 1980, vol. 22 (3), pp. 817-823. [cited by applicant]
Maddox, et al., Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein, J Exp Med., Oct. 1983, 158(4); pp. 1211-1226. [cited by applicant]
Maeda et al. “Construction of reshaped human antibodies with HIV-neutralizing activity.” Human Antibodies (1991); 2(3):124-134. [cited by applicant]
Martin, F. et al., “The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6,” EMBO Journal, Nov. 15, 1994, 13(22):5303-5309. [cited by applicant]
Mather, et al., Culture of testicular cells in hormone-supplemented serum-free medium, Annals of the New York Academy of Sciences, Jun. 1982, 383; pp. 44-68. [cited by applicant]
Mather, J.P. (1980). “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines,” Biol. Reprod., vol. 23, pp. 243-251. [cited by applicant]
Maxwell, et al., A simple in vivo assay for increased protein solubility, Protein Sci., Sep. 1999, 8(9); pp. 1908-1911. [cited by applicant]
Meagher, et al., Deconvolution of the fluorescence emission spectrum of human antithrombin and identification of the tryptophan residues that are responsive to heparin binding, J Biol Chem., 273(36):23283-23289 (1998). [cited by applicant]
Mullen, T.E., et al.; “Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential,” Antibody Therapeutics.; 4(3):185-196 (2021). [cited by applicant]
Muyldermans, S. et al., “Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains,” Protein Eng. 7(9):1129-1135 (1994). [cited by applicant]
Nagamine, et al., Electrochemical screening of recombinant protein solubility in [cited by applicant]
Neuberger, M., “Generating high-avidity human Mabs in mice, ” Nature Biotechnology, Jul. 1996, 14(7), pp. 826 (1page). [cited by applicant]
No, et al., Ecdysone-inducible gene expression in mammalian cells and transgenic mice, Proceedings of the National Academy of Sciences, Apr. 1996, 93(8); pp. 3346-3351. [cited by applicant]
Pardoll, D.M.; “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer; 12(4):252-264 (2012). [cited by applicant]
Park, S.Y., et al.; “Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases,” Biomedicines; 10(7):1750:1-17 (2022). [cited by applicant]
Peterson, et al., Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates, Bioconjug Chem.; 10(4):553-537 (1999). [cited by applicant]
Philips, G.K., et al.; “Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies,” International Immunology; 27(1):39-46 (2015). [cited by applicant]
Pilotte, L., et al.; “Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase,” PNAS USA; 109(7):2497-2502 (2012). [cited by applicant]
Pimenova, T., et al.; “Epitope mapping on bovine prion protein using chemical cross-linking and mass spectrometry,” J. Mass Spectrometry; 43(2):185-195 (2008). [cited by applicant]
Platten, M. et al.; “Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors,” Front Immunol.; 5:673; pp. 1-7 (2015). [cited by applicant]
Presta, L. G. et al., “Engineering therapeutic antibodies for improved function,” Biochemical Society Transactions (2002) 30(4):487-490. [cited by applicant]
Qing, et al., Cold-shock induced high-yield protein production in [cited by applicant]
Queen C. et al. (Dec. 1989), “A Humanized Antibody That Binds to the Interleukin 2 Receptor,” Proceedings of the National Academy of Sciences, vol. 86, No. 24, pp. 10029-10033. [cited by applicant]
RCSB Protein Data Bank: “RCSB PDB-3F62: Crystal Structure of Human IL-18 in complex with Ectromelia virus IL-18 Binding Protein,” Jan. 1, 2009 (Jan. 1, 2009), [retrieved on Jun. 12, 2024] from URL: https://www.rcsb.org/… [cited by applicant]
Reiter, Y., et al., “Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments,” Nature Biotechnology (Oct. 1996); 14(10):1239-1245. [cited by applicant]
Rhodes, et al., Transformation of maize by electroporation of embryos, Methods Mol Biol., 1995, 55; pp. 121-131. [cited by applicant]
Ridgway, J. B. B., et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization”, Protein Engineering, Design and Selection (1996); 9(7):617-621. [cited by applicant]
Riechmann, L., et al., “Reshaping human antibodies for therapy”, Nature (1988); 332(6162):323-327. [cited by applicant]
Robertson, M.J., et al.; “Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer,” Clinical Cancer Res.; 12(14 Pt 1):4265-4273 (2006). [cited by applicant]
Rosser, et al., Transient transfection of CHO-K1-S using serum-free medium in suspension: a rapid mammalian protein expression system, Protein Expr Purif., Apr. 2005, 40(2); pp. 237-243. [cited by applicant]
Sato et al. “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.” Cancer Research (1993); 53.4:851-856. [cited by applicant]
Schaer, D.A., et al.; “GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability,” Cancer Immunol Res.; 1(5):320-331 (2013). [cited by applicant]
Scharf et al., “Heat stress promoters and transcription factors,” Results Probl Cell Differ., 1994, 20:125-162. [cited by applicant]
Shao, Z., et al.; “CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction,” J Leukoc Biol.; 89(1):21-29 (2011). [cited by applicant]
Sharma, P., et al.; “The future of immune checkpoint therapy,” Science; 348(6230):56-61 (2015). [cited by applicant]
Sheridan, C.; “IDO inhibitors move center stage in immuno-oncology,” Nature Biotechnology; 33(4):321-322 (2015). [cited by applicant]
Shields et al. “High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR” Journal of Biological Chemistry (2001); 276(9… [cited by applicant]
Shields, et al., “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity.” The Journal of Biological Chemistry (2002); 277(30):26733-26740. [cited by applicant]
Shimp, et al., Production and characterization of clinical grade [cited by applicant]
Shinkawa T., et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharades Shows the Critical Role of Enhancing Antibody-dependent Cellular… [cited by applicant]
Silverman J., et al., “Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains,” Nature Biotechnology, Nature Publishing Group, Dec. 2005, vol. 23, No. 12, pp. 1556-1561. [cited by applicant]
Sitaraman, et al., High-throughput protein expression using cell-free system, Methods Mol Biol. 2009, 498; pp. 229-244. [cited by applicant]
Skerra, A. “Alternative binding proteins: anticalins—harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities”, FEBS J. (2008); 275(11):2677-2683. [cited by applicant]
Stenvall, et al., High-throughput solubility assay for purified recombinant protein immunogens, Biochim Biophys Acta., 1752(1):6-10 (2005). [cited by applicant]
Structural Genomics Consortium et al., “Protein Production and Purification,” Nature Methods, 2008, vol. 5 No. 2, pp. 135-146. [cited by applicant]
Stumpp et al., “DARPins: a true alternative to antibodies,” Curr Opin Drug Discov Devel., 10(2):153-159 (2007). [cited by applicant]
Tahara-Hanaoka, S., et al.; “Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112),” Int Immunol.; 16(4):533-538 (2004). [cited by applicant]
Takamatsu et al., “Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA,” EMBO J., (1987); 6(2):307-311. [cited by applicant]
Tempst P.R., et al., “Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo.” Nature Biotechnology, Mar. 1991, vol. 9 (3), pp. 266-271. [cited by applicant]
Thomas, L.J., et al.; “Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity,” Oncoimmunology; 3(1):e27255, pp. 1-4; doi:10.4161/onci.27255 (2014). [cited by applicant]
Topalian, S.L., et al.; “Immune checkpoint blockade: A common denominator approach to cancer therapy,” Cancer Cell.; 27(4):450-461 (2015). [cited by applicant]
Traunecker, A. et al., “Janusin: New molecular design for bispecific reagents,” Int J Cancer Suppl., Jan. 1992, vol. 7, pp. 51-52. [cited by applicant]
Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells,” The EMBO Journal, Dec. 1991, 10(12), pp. 3655-3659. [cited by applicant]
Tuerk et al., “Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase,” Science, 1990, 249(4968):505-510. [cited by applicant]
Umana P., et al., “Engineered Glycoforms of an Antineuroblastoma IgG1 With Optimized Antibody-dependent Cellular Cytotoxic Activity,” Nature Biotechnology, Feb. 1999, vol. 17, No. 2, pp. 176-180. [cited by applicant]
UniProtKB O95998 (Gene ID: 10068) IL18BP “Interleukin-18-binding protein,” Jul. 7, 2009 version 2; [retrieved online Sep. 12, 2024] URL: https://www.uniprot.org/uniprotkb/095998/entry, 10 pages. [cited by applicant]
Urlaub et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc. Natl. Acad. Sci. USA, 1980, 77(7), pp. 4216-4220. [cited by applicant]
Van Heeke et al, “Expression of Human Asparagine Synthetase in [cited by applicant]
Vecchie, A., et al.; “IL-18 and infections: Is there a role for targeted therapies?” J Cell Physiol.; 236(3):1638-1657; Epub Aug. 13, 2020, 20 pages (2021). [cited by applicant]
Verhoeyen, M. et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science 239(4847):1534-1536 (1988). [cited by applicant]
Vonderheide, R.H., et al.; “Agonistic CD40 antibodies and cancer therapy,” Clin Cancer Res.; 19(5):1035-1043 (2013). [cited by applicant]
Wang, T., et al.; “IL-18 and IL-18 Binding Protein Are Related to Disease Severity of Myelodysplastic Syndromes,” Blood; 140(Suppl. 1):12297, 1 page (2022). [cited by applicant]
Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wigler et al., “Transformation of mammalian cells with an amplifiable dominant-acting gene,” Proceedings of the National Academy and Sciences, vol. 77, No. 6, Jun. 1980, pp. 3567-3570. [cited by applicant]
Wigler M., et al.; “Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells,” Cell, 11(1):223-232 (1977). [cited by applicant]
Wigley, et al., “Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein,” Nature Biotechnology, 19(2):131-136 (2001). [cited by applicant]
Wildt, et al., The humanization of N-glycosylation pathways in yeast, Nat Rev Microbiol, Feb. 2005, 53(2):119-128. [cited by applicant]
Winter, et al., The expression of heat shock protein and cognate genes during plant development, Results Probl Cell Differ. 1991, 17; pp. 85-105. [cited by applicant]
Witherden, D.A., et al.; “1076: Discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity,” Journal for Immuno Therapy of Cancer (2023); 11(Supp 1):A1-A1731, p. A1185, Abstract only; doi: 10.113… [cited by applicant]
Workman, C.J., et al.; “Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo,” J Immunol.; 172(9):5450-5455 (2004). [cited by applicant]
Workman, C.J., et al.; “The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells,” Eur J Immunol.; 33(4):970-979 (2003). [cited by applicant]
Worn, A. et al. “Stability Engineering of Antibody Single-chain Fv Fragments,” J. Mol.Biol., 2001, 305(5):989-1010. [cited by applicant]
Yazaki, et al., “Expression of recombinant antibodies in mammalian cell lines,” Methods Mol Biol., 248:255-268 (2004). [cited by applicant]
Zhou, T., et al.; “IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy,” Nature. 583(7817):609-614, 29 pages (2020). [cited by applicant]
Zimmermann, K., “A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F(ab′)2 fragments,” Nucl Med Biol., 1999; 26(8):943-950. [cited by applicant]
Zuckerman et al., “The characterization and functional significance of plasma membrane Fc Receptors,” CRC Crit Rev Microbiol., 7(1):1-26 (1978). [cited by applicant]